Association Between Tumor Expression of VEGFA, VEGFR1 (FLT1), VEGFR2 (KDR), and Clinical Outcomes in Neuroendocrine Tumors

#823

Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).

Aim(s): We investigated the prognostic significance of expression of VEGF pathway components in NET patients generally, and in a subgroup of patients treated with bevacizumab.

Materials and methods: We evaluated immunohistochemical expression of VEGFA, VEGFR1, and VEGFR2 in a cohort of archival NETs and evaluated associations with overall survival (OS) and progression-free survival (PFS) after adjusting for other clinical prognostic variables.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Qian Z

Authors: Qian Z, Ter-Minassian M, Chan J, Imamura Y, Hooshmand S,

Keywords: VEGF, bevacizumab, NET survival,

To read the full abstract, please log into your ENETS Member account.